ORAL DRUG ABUSE: DETERMINANTS AND CONSEQUENCES

口服药物滥用：决定因素和后果

• 批准号: 3075466
• 负责人: JOHN L FALK
• 金额: $ 9.92万
• 依托单位: RUTGERS, THE STATE UNIV OF N.J.
• 依托单位国家: 美国
• 财政年份: 1990
• 资助国家: 美国
• 起止时间: 1990-01-01 至 1994-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3075466
• 关键词: albino rat; alcoholism /alcohol abuse; benzodiazepines; blood chemistry; caffeine; desipramine; drug abuse; drug abuse chemotherapy; drug addiction antagonist; drug administration rate /duration; drug administration routes; drug interactions; drug tolerance; drug withdrawal; nicotine; psychomotor function; self destructive behavior; tranquilizer

The determinants and consequences of excessive oral drug self- administration by schedule-induced polydipsia will be explored, emphasizing oral cocaine (COC) and benzodiazepine (BZ) abuse variables and fine-motor performance consequences: (A: COC) (1) The amelioration of excessive COC intake by acute and chronic treatment with possible therapeutic agents (e.g., desipramine, mazindol) and by (2) alternatives to COC ingestion (e.g., other solutions, activity wheel). (3) Exacerbation of COC abuse by injections of nicotine (NIC) and caffeine (CAF). (4) The gateways to exacerbated COC abuse by first instituting a history of licit-drug polydipsia (NIC, CAF), and (5) possible behavioral immunization (history of situational alternatives) against COC abuse acquisition. The consequences of acute and chronic injection and withdrawal of COC for discriminative motor performance, as well as COC interactions with NIC and CAF. (B: BZ) (1) The amelioration of excessive BZ intake by blockers (Ro 15-1788, CGS 8216) and (2) its exacerbation by CAF or a history of sedative (ethanol) abuse. (3) Acute and chronic drug anxiolytic action evaluation by a method employing the exaggerated ingestion of NaC1 solutions by such agents. (3) The fine motor control consequences of daily rebound from chronic exposure to midazolam (e.g., as perhaps exaggerated by inverse agonist [FG 7142] probes) and of midazolam- CAF interactions. For both COC and BZs, serum levels of drug and metabolites will be measured, both with respect to chronic amounts abused and the levels associated with motor performance disruption.

过量口服药物自我治疗的决定因素和后果 将探索通过日程诱发的烦渴进行给药， 强调口服可卡因（COC）和苯二氮卓类（BZ）滥用变量和 精细运动表现后果：（A：COC）（1）改善 急性和慢性治疗可能导致过量COC摄入 治疗剂（例如地昔帕明、马吲哚）和 (2) 替代品 COC 摄入（例如其他溶液、活动轮）。 (3) 注射尼古丁 (NIC) 和咖啡因会加剧 COC 滥用 （非洲足协）。 (4) 首先建立一个可能加剧 COC 滥用的途径 合法药物烦渴病史（NIC、CAF），以及 (5) 可能的行为 针对 COC 滥用的免疫接种（情景替代方案的历史） 获得。 急性和慢性注射的后果和 因歧视性运动表现而撤销 COC，以及 COC 与 NIC 和 CAF 交互。 (B: BZ) (1) 改善过度 阻滞剂摄入 BZ（Ro 15-1788，CGS 8216）和 (2) 其恶化 CAF 或镇静剂（乙醇）滥用史。 （三）急、慢性药物 采用夸张法评价抗焦虑作用 此类制剂摄入 NaC1 溶液。 (3)精细动作控制 长期接触咪达唑仑而每日反弹的后果（例如， 可能被反向激动剂 [FG 7142] 探针夸大）和咪达唑仑- CAF 互动。 对于 COC 和 BZ，药物和 BZ 的血清水平 将测量代谢物，包括长期滥用的量 以及与运动表现中断相关的水平。